News
12-09-2022, 10:02 AM
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.
More... (https://www.news-medical.net/news/20221209/Addition-of-capivasertib-to-fulvestrant-doubles-progression-free-survival-in-HR-positive-breast-cancer-patients.aspx)
More... (https://www.news-medical.net/news/20221209/Addition-of-capivasertib-to-fulvestrant-doubles-progression-free-survival-in-HR-positive-breast-cancer-patients.aspx)